Macquarie Group
YMAB

Macquarie Group’s Y-mAbs Therapeutics YMAB Stock Holding History

Macquarie Group’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-209
Closed -$7K – 2156
2022
Q3 		$7K Sell
209
-262
-56% -$4.34K ﹤0.01% 2418
2022
Q2 		$7K Hold
471
– – ﹤0.01% 2496
2022
Q1 		$6 Hold
471
– – ﹤0.01% 2583
2021
Q4 		$8K Hold
471
– – ﹤0.01% 2542
2021
Q3 		$13K Hold
471
– – ﹤0.01% 2519
2021
Q2 		$16K Hold
471
– – ﹤0.01% 2408
2021
Q1 		$14K Sell
471
-124
-21% -$5.08K ﹤0.01% 2351
2020
Q4 		$29K Hold
595
– – ﹤0.01% 2154
2020
Q3 		$23K Hold
595
– – ﹤0.01% 2144
2020
Q2 		$26K Buy
+595
New +$22.5K ﹤0.01% 2108

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Macquarie Group's YMAB Position: Q4 2022 in Review

Macquarie Group sold out of Y-mAbs Therapeutics (YMAB) in Q4 2022, closing a stake of 209 shares — an estimated $7K sold.

Macquarie Group first reported a position in YMAB in Q2 2020 and held it in 10 quarters. The position peaked at $29K in Q4 2020. 91 funds tracked by Wall St. Rank hold YMAB as of Q4 2022.

  • Macquarie Group reported no remaining Y-mAbs Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Macquarie Group sold 209 Y-mAbs Therapeutics shares in Q4 2022, an estimated $7K.
  • Macquarie Group first reported a position in Y-mAbs Therapeutics in Q2 2020 and held it in 10 quarters.
  • Macquarie Group's Y-mAbs Therapeutics position peaked at $29K in Q4 2020.
  • 91 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2022.

Based on Macquarie Group's 13F filing for Q4 2022, filed 21 Feb 2023.